Mostly Markets
Subscribe
Stocks/Health Care/Pharmaceuticals

PfizerPFE

Pharmaceuticals · New York City, New York · In the S&P 500
Solid businessCheaper than peers
$30.52+1.90%After hours: $30.45 (−0.22%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 25.6% over 1 year
Pfizer over 1 yearDaily close, $, to 30 Oct 2026
$24$26$28$30Nov2026MarMayJulSep$30.52$25$28NovMarJul$30.52
Source: Nasdaq daily closes
Market value$174B
Price to earnings40.4x
Forward P/E11.1x
Dividend yield5.64%
Year to date+22.6%
One year+25.6%
Next earningsTue 3 Nov, before the open
SectorHealth Care
52-week range (closes)
$23.67$30.52

Quality and valuation

How Pfizer compares with other health care stocks. A description, not a recommendation.

Pfizer and 4 pharmaceuticals peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: cheaper than most

An average business among health care companies, priced below most of them.

Pfizer trades at 11.1 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: −0.2% vs +8.1%
  • Keeps more of each sale (gross margin): 73.2% vs 65.0%
  • Turns more of its sales into cash: 17.2% vs 15.9%
  • Keeps less of its revenue as profit (net margin): 6.8% vs 9.7%
PFE trades at 11.1x forward earnings, below the sector medianForward p/e, Pharmaceuticals peers
BMY10.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1xBMY10.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1x
Source: CNBC quotes; Mostly Markets

Financials

From Pfizer's SEC filings, through the quarter ending 28 Jun 2026. Hover or tap a bar for its value.

Revenue grew 2.6% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0bn$5bn$10bn$15bnQ3 ’24Q1 ’25Q3 ’25$15.0bnQ2 ’26$0bn$10bnQ3 ’24Q1 ’25Q3 ’25$15.0bnQ2 ’26
Source: SEC filings
Growth slowed to +2.6% last quarterRevenue growth, year on year, %
0%10%20%30%Q3 ’24Q1 ’25Q3 ’252.6%Q2 ’260%20%Q3 ’24Q1 ’25Q3 ’252.6%Q2 ’26
Source: SEC filings
Free cash flow was $11.0 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0bn$2bn$4bn$6bnQ3 ’24Q1 ’25Q3 ’25$0.3bnQ2 ’26$0bn$2bn$5bnQ3 ’24Q1 ’25Q3 ’25$0.3bnQ2 ’26
Source: SEC filings
Diluted EPS was $-0.04 last quarterQuarterly diluted earnings per share, $
$0.0$0.5Q3 ’24Q1 ’25Q3 ’25−$0.04Q2 ’26$0.0$0.5Q3 ’24Q1 ’25Q3 ’25−$0.04Q2 ’26
Source: SEC filings
Last 12 monthsPFESector median
Revenue growth−0.2%+8.1%
Gross margin73.2%65.0%
Free cash flow margin17.2%15.9%
Price to earnings40.4x30.2x

Stories on Pfizer

We haven't written about Pfizer yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Pharmaceuticals, by market value.

CompanyPriceTodayYTDValue
LLYEli Lilly$1,417.54+3.19%+31.9%$1.33T
JNJJohnson & Johnson$273.20−0.73%+32.0%$658B
MRKMerck$149.52+2.18%+42.0%$369B
NVSNovartis$160.79−0.19%+16.6%$327B
AZNAstraZeneca$186.65+7.02%+6.4%$290B
NVONovo Nordisk$40.00+2.20%−21.4%$136B
BMYBristol Myers Squibb$62.48+1.78%+15.8%$128B
ZTSZoetis$79.72+1.85%−37.4%$32.94B